마이크로톰 시장 : 2027년 세계 예측

출판 : MarketsandMarkets(마켓츠앤드마켓츠)출판년월 : 2022년05월

마이크로톰 시장 : 제품(장비, (회전식), 액세서리(마이크로톰 블레이드), 애플리케이션(질환 진단, 의학 연구), 기술(전자동, 반자동, 수동), 최종 사용자(병원, 임상 실험실) – 2027년 세계 예측

Microtome Market by Product (Instruments, (Rotary), Accessories (Microtome Blades), Application (Disease Diagnosis, Medical Research), Technology (Fully Automated, Semi-automated, Manual), End User (Hospital, Clinical Labs) – Global Forecast to 2027

페이지수 211
도표수 295
구성 영문조사보고서
가격

리포트목차    주문/문의    납기/라이센스안내

Sample Request

Based on End user the market is classified into, The hospital laboratories, clinical laboratories, and other end users . The growth of this market is majorly driven by the increasing number of specialty diagnostic tests performed in hospital laboratories, rising number of in-house clinical diagnostic procedures in hospitals, rising number of hospitals across the globe, and the growing trend of establishing in-house clinical diagnostic capabilities in hospitals.
최종 사용자에 따라 시장은 병원 실험실, 임상 실험실 및 기타 최종 사용자로 분류됩니다. 이 시장의 성장은 주로 병원 실험실에서 수행되는 전문 진단 테스트의 수 증가, 병원에서 자체 임상 진단 절차의 수 증가, 전 세계적으로 증가하는 병원 수 및 사내 구축의 증가 추세에 의해 주도됩니다.

“Microtome instruments in the product segment to witness the highest shares during the forecast period.”
Based on the product, the microtome market is segmented into Microtome Instruments: Rotary Microtomes, Cryostat Microtomes, Vibrating Microtomes, Other Microtomes, and Microtome Accessories. The microtome instruments segment is expected to dominate the microtome market. High expenditure on microtome instruments and their essential use in the histological diagnosis of various diseases are the key factors driving the growth of the automated microtome market.

“Asia Pacific is estimated to register the highest CAGR during the forecast period.”

In this report, the microtome market is segmented into four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). The market in Asia Pacific is projected to register the highest growth rate during the forecast period. The growth in this market is primarily driven by the rising disposable income of the middle-class population, infrastructural developments, and the rising penetration of diagnostic technologies in Asian countries such as India and China in addition, the rising incidence of cancer and the growing focus of global medical device companies on expanding their presence in emerging Asia Pacific countries are some of the key factors.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (32%) , Tier 2 (44%), and Tier 3 (24%)

• By Designation: C-level (30%), Director-level (34%), and Others (36%)

• By Region: North America (40%), Europe (28%), AsiaPacific (20%), and Rest of the World(12%)

List of Companies Profiled in the Report

• Danaher Corporation (US)
• Boeckeler Instruments, Inc (US)
• SM Scientific Instruments Pvt. Ltd. (India)
• PHC holdings corporation (Japan)
• Cardinal Health (US)
• Bright Instruments (UK)
• Sakura Finetek USA, Inc (US)
• Jinhua Yidi Medical Equipment Co., Ltd (China)
• Ted Pella, Inc (US)
• Medimeas (India)
• SLEE medical GmbH (Germany)
• Histo-Line Laboratories (Italy)
• microTec Laborgeräte GmbH (Germany)
• MEDITE Medical GmbH (Germany)
• Campden Instruments. (UK)
• Lupetec (Brazil)
• AGD BIOMEDICALS PVT LTD (India)
• Lafayette Instrument Company (US)
• MILESTONE MEDICAL (US)
• Diapath S.p.A. (Italy)
• RWD Life Science Co., LTD (China)
• LABOID INTERNATIONAL (India)
• Shenzhen Dakewei Biotechnology Co., Ltd. (China)
• Amos scientific Pty Ltd (Australia)
• Campden Instruments. (UK)

Research Coverage:
This report studies the microtome market based on product, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total microtome market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report:
The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on microtome products offered by the top 25 players in the microtome market. The report analyzes the microtome market by product, and region.

• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.

• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the microtme market

• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the microtome market


목차

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 29)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 YEARS COVERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 MARKET STAKEHOLDERS
1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. – 33)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primary interviews
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: DANAHER CORPORATION
FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1 GROWTH FORECAST
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 8 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 9 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 ASSUMPTIONS FOR THE STUDY
2.6 INDICATORS AND ASSUMPTIONS AND  THEIR IMPACT ON THE STUDY
2.6.1 COVID-19-SPECIFIC ASSUMPTIONS
2.7 RISK ASSESSMENT
TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. – 46)
FIGURE 10 MICROTOMES MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION)
FIGURE 11 MICROTOMES MARKET, BY TECHNOLOGY,  2022 VS. 2027 (USD MILLION)
FIGURE 12 MICROTOMES MARKET, BY APPLICATION,  2022 VS. 2027 (USD MILLION)
FIGURE 13 MICROTOMES MARKET, BY END USER,  2022 VS. 2027 (USD MILLION)
FIGURE 14 GLOBAL MICROTOMES MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS (Page No. – 50)
4.1 MICROTOMES MARKET OVERVIEW
FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
4.2 MICROTOMES MARKET, BY PRODUCT
FIGURE 16 FULLY AUTOMATED MICROTOMES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD
4.3 ASIA PACIFIC: MICROTOMES MARKET,  BY PRODUCT AND COUNTRY
FIGURE 17 ROTARY MICROTOMES SEGMENT WILL DOMINATE APAC MARKET DURING FORECAST PERIOD
4.4 GEOGRAPHIC SNAPSHOT OF MICROTOMES MARKET
FIGURE 18 MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 53)
    5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 19 MICROTOMES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising prevalence of cancer
TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
5.2.1.2 Growing demand for digital pathology
5.2.1.3 Recommendations for cancer screening
5.2.1.4 Availability of reimbursement
5.2.2 CHALLENGES
5.2.2.1 Lack of skilled professionals
TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
5.2.2.2 Availability of refurbished products
5.2.3 OPPORTUNITIES
5.2.3.1 Growing focus on personalized medicine
5.2.3.2 Emerging economies
5.3 IMPACT OF COVID-19 ON MICROTOMES MARKET
5.4 RANGES/SCENARIOS
5.4.1 MICROTOMES MARKET
FIGURE 20 PESSIMISTIC SCENARIO
FIGURE 21 OPTIMISTIC SCENARIO
FIGURE 22 REALISTIC SCENARIO
5.5 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASE
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 24 DIRECT DISTRIBUTION—PREFERRED STRATEGY FOR PROMINENT COMPANIES
5.7 TECHNOLOGY ANALYSIS
5.8 PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT OF NEW ENTRANTS
5.8.2 INTENSITY OF COMPETITIVE RIVALRY
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 THREAT OF SUBSTITUTES
5.9 KEY STAKEHOLDERS & BUYING CRITERIA
5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS
TABLE 5 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 2 END USERS
5.9.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR TOP 2 END USERS
TABLE 6 KEY BUYING CRITERIA FOR TOP 2 END USERS
5.10 REGULATORY LANDSCAPE
TABLE 7 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING MICROTOMES MARKET
5.11 PATENT ANALYSIS
5.12 KEY CONFERENCES & EVENTS IN 2022
TABLE 8 LIST OF CONFERENCES & EVENTS
5.13 PRICING ANALYSIS
TABLE 9 PRICE RANGE FOR MICROTOMES
5.14 TRADE ANALYSIS
TABLE 10 IMPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF  INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
TABLE 11 EXPORT DATA FOR MICROTOMES AND PARTS AND ACCESSORIES OF  INSTRUMENTS & APPARATUS FOR PHYSICAL OR CHEMICAL ANALYSIS, BY COUNTRY, 2016–2020 (USD MILLION)
5.15 ECOSYSTEM ANALYSIS
5.15.1 ROLE IN ECOSYSTEM
5.15.2 KEY PLAYERS OPERATING IN MICROTOMES MARKET
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES

6 MICROTOMES MARKET, BY PRODUCT (Page No. – 74)
    6.1 INTRODUCTION
TABLE 12 MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 13 MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
6.2 MICROTOME INSTRUMENTS
TABLE 14 MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 15 MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 16 MICROTOME INSTRUMENTS MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 17 MICROTOME INSTRUMENTS MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.1 ROTARY MICROTOMES
6.2.1.1 Rotary microtomes are widely used in histology laboratories
TABLE 18 ROTARY MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 19 ROTARY MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 20 ROTARY MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.2 CRYOSTAT MICROTOMES
6.2.2.1 Cryostat microtomes provide immediate results by quickly, reliably, and safely cutting accurate frozen sections
TABLE 21 CRYOSTAT MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 22 CRYOSTAT MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 23 CRYOSTAT MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.3 VIBRATING MICROTOMES
6.2.3.1 Vibrating microtomes are designed to cut fresh tissue specimens
TABLE 24 VIBRATING MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 25 VIBRATING MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 26 VIBRATING MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)
6.2.4 OTHER MICROTOMES
TABLE 27 OTHER MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 28 OTHER MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 29 OTHER MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3 MICROTOME ACCESSORIES
TABLE 30 MICROTOME ACCESSORIES MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 31 MICROTOME ACCESSORIES MARKET, BY TYPE, 2021–2027 (USD MILLION)
6.3.1 MICROTOME BLADES
6.3.1.1 Adoption of disposable blades has increased among end users
TABLE 32 MICROTOME BLADES OFFERED BY MARKET PLAYERS
TABLE 33 MICROTOME BLADES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 34 MICROTOME BLADES MARKET, BY REGION, 2021–2027 (USD MILLION)
6.3.2 OTHER MICROTOME ACCESSORIES
TABLE 35 OTHER MICROTOME ACCESSORIES OFFERED BY MARKET PLAYERS
TABLE 36 OTHER MICROTOME ACCESSORIES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 37 OTHER MICROTOME ACCESSORIES MARKET, BY REGION, 2021–2027 (USD MILLION)

7 MICROTOMES MARKET, BY TECHNOLOGY (Page No. – 89)
7.1 INTRODUCTION
TABLE 38 MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 39 MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
7.2 MANUAL MICROTOMES
7.2.1 LOWER COST AND USER COMFORT ASSOCIATED WITH THESE MICROTOMES ARE DRIVING THEIR ADOPTION
TABLE 40 MANUAL MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 41 MANUAL MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 42 MANUAL MICROTOMES MARKET, BY REGION, 2021–2027 USD MILLION)
7.3 SEMI-AUTOMATED MICROTOMES
7.3.1 SEMI-AUTOMATED MICROTOMES SEGMENT TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
TABLE 43 SEMI-AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 44 SEMI-AUTOMATED MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 45 SEMI-AUTOMATED MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)
7.4 FULLY AUTOMATED MICROTOMES
7.4.1 LACK OF CLINICAL LABORATORY TECHNICIANS AND HIGH PREVALENCE OF CANCER HAVE DRIVEN SEGMENT GROWTH
TABLE 46 FULLY AUTOMATED MICROTOMES OFFERED BY MARKET PLAYERS
TABLE 47 FULLY AUTOMATED MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 48 FULLY AUTOMATED MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)

8 MICROTOMES MARKET, BY APPLICATION (Page No. – 95)
8.1 INTRODUCTION
TABLE 49 MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 50 MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
8.2 DISEASE DIAGNOSIS
8.2.1 EXPANDING POOL OF GERIATRIC PATIENTS AND INCREASING DIAGNOSIS OF CHRONIC DISEASES DRIVING SEGMENT GROWTH
TABLE 51 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
TABLE 52 MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2017–2020 (USD MILLION)
TABLE 53 MICROTOMES MARKET FOR DISEASE DIAGNOSIS, BY REGION, 2021–2027 (USD MILLION)
8.3 MEDICAL RESEARCH
8.3.1 INCREASING RESEARCH ACTIVITIES TO DRIVE  ADOPTION OF MICROTOMES
TABLE 54 MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION, 2017–2020 (USD MILLION)
TABLE 55 MICROTOMES MARKET FOR MEDICAL RESEARCH, BY REGION, 2021–2027 (USD MILLION)

9 MICROTOMES MARKET, BY END USER (Page No. – 99)
9.1 INTRODUCTION
TABLE 56 MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 57 MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
9.2 HOSPITAL LABORATORIES
9.2.1 HOSPITAL LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2021
TABLE 58 MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2017–2020 (USD MILLION)
TABLE 59 MICROTOMES MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2021–2027 (USD MILLION)
9.3 CLINICAL LABORATORIES
9.3.1 PRESENCE OF ROBUST INFRASTRUCTURE TO PERFORM TESTS IN HIGH VOLUMES IS ESTIMATED TO DRIVE MARKET GROWTH
TABLE 60 MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION, 2017–2020 (USD MILLION)
TABLE 61 MICROTOMES MARKET FOR CLINICAL LABORATORIES, BY REGION, 2021–2027 (USD MILLION)
9.4 OTHER END USERS
TABLE 62 MICROTOMES MARKET FOR OTHER END USERS, BY REGION, 2017–2020 (USD MILLION)
TABLE 63 MICROTOMES MARKET FOR OTHER END USERS, BY REGION, 2021–2027 (USD MILLION)

10 MICROTOMES MARKET, BY REGION (Page No. – 104)
10.1 INTRODUCTION
TABLE 64 MICROTOMES MARKET, BY REGION, 2017–2020 (USD MILLION)
TABLE 65 MICROTOMES MARKET, BY REGION, 2021–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 27 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 28 NORTH AMERICA: MICROTOMES MARKET SNAPSHOT
TABLE 66 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 67 NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 69 NORTH AMERICA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 71 NORTH AMERICA: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 73 NORTH AMERICA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 74 NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 75 NORTH AMERICA: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 76 NORTH AMERICA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 77 NORTH AMERICA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.2.1 US
10.2.1.1 High burden of cancer and numerous conferences on anatomic pathology to drive market growth
TABLE 78 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 79 US: KEY MACROINDICATORS
TABLE 80 US: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 81 US: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 82 US: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 83 US: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 84 US: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 85 US: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 86 US: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 87 US: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Availability of research funding and rising incidence of cancer to drive market growth
TABLE 88 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 89 CANADA: KEY MACROINDICATORS
TABLE 90 CANADA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 91 CANADA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 92 CANADA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 93 CANADA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 94 CANADA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 95 CANADA: MICROTOMES MARKET, BY TECHNOLOGY,  2021–2027 (USD MILLION)
TABLE 96 CANADA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 97 CANADA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3 EUROPE
FIGURE 29 EUROPE: CANCER INCIDENCE & MORTALITY, 2012–2035
TABLE 98 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
TABLE 99 EUROPE: MICROTOMES MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 100 EUROPE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 101 EUROPE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 102 EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 103 EUROPE: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 104 EUROPE: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 105 EUROPE: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 106 EUROPE: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 107 EUROPE: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 108 EUROPE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 109 EUROPE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Increasing prevalence of chronic diseases to drive market growth
TABLE 110 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 111 GERMANY: MICROTOMES MARKET, BY PRODUCT,  2017–2020 (USD MILLION)
TABLE 112 GERMANY: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 113 GERMANY: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 114 GERMANY: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 115 GERMANY: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 116 GERMANY: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 117 GERMANY: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 118 GERMANY: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3.2 FRANCE
10.3.2.1 High prevalence of cancer to support market growth in France
TABLE 119 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 120 FRANCE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 121 FRANCE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 122 FRANCE: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 123 FRANCE: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 124 FRANCE: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 125 FRANCE: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 126 FRANCE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 127 FRANCE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3.3 UK
10.3.3.1 Favorable government initiatives to drive market growth
TABLE 128 UK: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 129 UK: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 130 UK: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 131 UK: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 132 UK: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 133 UK: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 134 UK: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 135 UK: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 High prevalence of cancer and increasing per capita healthcare spending to support market growth in Italy
TABLE 136 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 137 ITALY: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 138 ITALY: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 139 ITALY: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 140 ITALY: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 141 ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 142 ITALY: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 143 ITALY: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 144 ITALY: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 High incidence of chronic diseases to drive market growth  in Spain
TABLE 145 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 146 SPAIN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 147 SPAIN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 148 SPAIN: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 149 SPAIN: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 150 SPAIN: MICROTOMES MARKET, BY TECHNOLOGY,  2017–2020 (USD MILLION)
TABLE 151 SPAIN: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 152 SPAIN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 153 SPAIN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.3.6 REST OF EUROPE
TABLE 154 LUNG CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040
TABLE 155 LIVER CANCER INCIDENCE IN KEY ROE COUNTRIES, 2020 VS. 2040
TABLE 156 ROE: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 157 ROE: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 158 ROE: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 159 ROE: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 160 ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 161 ROE: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 162 ROE: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 163 ROE: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 30 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012–2035
FIGURE 31 ASIA PACIFIC: MICROTOMES MARKET SNAPSHOT
TABLE 164 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY,  2017–2020 (USD MILLION)
TABLE 165 ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY, 2021–2027 (USD MILLION)
TABLE 166 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT,  2017–2020 (USD MILLION)
TABLE 167 ASIA PACIFIC: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 168 ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE,  2017–2020 (USD MILLION)
TABLE 169 ASIA PACIFIC: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 171 ASIA PACIFIC: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 172 ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY,  2017–2020 (USD MILLION)
TABLE 173 ASIA PACIFIC: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 174 ASIA PACIFIC: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 175 ASIA PACIFIC: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Presence of well-developed healthcare system to support market growth in Japan
TABLE 176 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
TABLE 177 JAPAN: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 178 JAPAN: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 179 JAPAN: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 180 JAPAN: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 181 JAPAN: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 182 JAPAN: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 183 JAPAN: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 184 JAPAN: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 Rising healthcare expenditure to drive market growth in China
TABLE 185 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 186 CHINA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 187 CHINA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 188 CHINA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 189 CHINA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 190 CHINA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 191 CHINA: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 192 CHINA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 193 CHINA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Growing healthcare sector to drive market growth in India
TABLE 194 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 195 INDIA: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 196 INDIA: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 197 INDIA: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 198 INDIA: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 199 INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 200 INDIA: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 201 INDIA: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 202 INDIA: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.4.4 REST OF ASIA PACIFIC
TABLE 203 ROAPAC: INCIDENCE OF CANCER, BY COUNTRY, 2020 VS. 2040
TABLE 204 ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 205 ROAPAC: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 206 ROAPAC: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 207 ROAPAC: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 208 ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 209 ROAPAC: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 210 ROAPAC: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 211 ROAPAC: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)
10.5 REST OF THE WORLD
TABLE 212 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 213 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES,  2018 VS. 2025
TABLE 214 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
TABLE 215 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
TABLE 216 ROW: MICROTOMES MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
TABLE 217 ROW: MICROTOMES MARKET, BY PRODUCT, 2021–2027 (USD MILLION)
TABLE 218 ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2017–2020 (USD MILLION)
TABLE 219 ROW: MICROTOME INSTRUMENTS MARKET, BY TYPE, 2021–2027 (USD MILLION)
TABLE 220 ROW: MICROTOMES MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
TABLE 221 ROW: MICROTOMES MARKET, BY APPLICATION, 2021–2027 (USD MILLION)
TABLE 222 ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2017–2020 (USD MILLION)
TABLE 223 ROW: MICROTOMES MARKET, BY TECHNOLOGY, 2021–2027 (USD MILLION)
TABLE 224 ROW: MICROTOMES MARKET, BY END USER, 2017–2020 (USD MILLION)
TABLE 225 ROW: MICROTOMES MARKET, BY END USER, 2021–2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. – 160)
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
TABLE 226 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS
11.3 MARKET SHARE ANALYSIS
TABLE 227 MICROTOMES MARKET: DEGREE OF COMPETITION
11.4 COMPANY EVALUATION MATRIX
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 32 COMPANY EVALUATION MATRIX: MICROTOMES MARKET
11.5 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
11.5.1 PROGRESSIVE COMPANIES
11.5.2 STARTING BLOCKS
11.5.3 RESPONSIVE COMPANIES
11.5.4 DYNAMIC COMPANIES
FIGURE 33 COMPANY EVALUATION MATRIX FOR SMES/START-UPS: MICROTOMES MARKET
11.6 COMPANY FOOTPRINT ANALYSIS
TABLE 228 OVERALL FOOTPRINT OF COMPANIES
TABLE 229 REGIONAL FOOTPRINT OF COMPANIES
TABLE 230 PRODUCT FOOTPRINT OF COMPANIES
11.7 COMPETITIVE BENCHMARKING
TABLE 231 MICROTOMES MARKET: DETAILED LIST OF KEY START-UPS/SMES
11.8 COMPETITIVE SCENARIO
11.8.1 PRODUCT LAUNCHES
TABLE 232 KEY PRODUCT LAUNCHES
11.8.2 DEALS
TABLE 233 KEY DEALS
11.8.3 OTHER DEVELOPMENTS
TABLE 234 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES (Page No. – 171)
     12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION
TABLE 235 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 34 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.2 PHC HOLDINGS CORPORATION
TABLE 236 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 35 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
12.1.3 CARDINAL HEALTH
TABLE 237 CARDINAL HEALTH: BUSINESS OVERVIEW
FIGURE 36 CARDINAL HEALTH: COMPANY SNAPSHOT (2021)
12.1.4 BOECKELER INSTRUMENTS, INC.
TABLE 238 BOECKELER INSTRUMENTS, INC.: BUSINESS OVERVIEW
12.1.5 BRIGHT INSTRUMENTS LTD.
TABLE 239 BRIGHT INSTRUMENTS LTD.: BUSINESS OVERVIEW
12.1.6 ERMA INC.
TABLE 240 ERMA INC.: BUSINESS OVERVIEW
12.1.7 HISTO-LINE LABORATORIES
TABLE 241 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
12.1.8 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.
TABLE 242 JINHUA YIDI MEDICAL APPLIANCE CO., LTD.: BUSINESS OVERVIEW
12.1.9 MEDIMEAS
TABLE 243 MEDIMEAS: BUSINESS OVERVIEW
12.1.10 MEDITE MEDICAL GMBH
TABLE 244 MEDITE MEDICAL GMBH: BUSINESS OVERVIEW
12.1.11 MICROTEC LABORGERÄTE GMBH
TABLE 245 MICROTEC LABORGERÄTE GMBH: BUSINESS OVERVIEW
12.1.12 SAKURA FINETEK USA, INC.
TABLE 246 SAKURA FINETEK USA, INC.: BUSINESS OVERVIEW
12.1.13 SLEE MEDICAL GMBH
TABLE 247 SLEE MEDICAL GMBH: BUSINESS OVERVIEW
12.1.14 SM SCIENTIFIC INSTRUMENTS PVT. LTD.
TABLE 248 SM SCIENTIFIC INSTRUMENTS PVT. LTD.: BUSINESS OVERVIEW
12.1.15 TED PELLA, INC.
TABLE 249 TED PELLA, INC.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 AGD BIOMEDICALS PVT. LTD.
TABLE 250 AGD BIOMEDICALS PVT. LTD.: BUSINESS OVERVIEW
12.2.2 AMOS SCIENTIFIC PTY LTD.
TABLE 251 AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW
12.2.3 CAMPDEN INSTRUMENTS LTD.
TABLE 252 CAMPDEN INSTRUMENTS LTD.: BUSINESS OVERVIEW
12.2.4 DIAPATH S.P.A.
TABLE 253 DIAPATH S.P.A.: BUSINESS OVERVIEW
12.2.5 LABOID INTERNATIONAL
TABLE 254 LABOID INTERNATIONAL: BUSINESS OVERVIEW
12.2.6 LAFAYETTE INSTRUMENT COMPANY
TABLE 255 LAFAYETTE INSTRUMENT COMPANY: BUSINESS OVERVIEW
12.2.7 LUPETEC
TABLE 256 LUPETEC: BUSINESS OVERVIEW
12.2.8 MILESTONE MEDICAL
TABLE 257 MILESTONE MEDICAL: BUSINESS OVERVIEW
12.2.9 RWD LIFE SCIENCE CO., LTD.
TABLE 258 RWD LIFE SCIENCE CO., LTD.: BUSINESS OVERVIEW
12.2.10 SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD.
TABLE 259 SHENZHEN DAKEWEI BIOTECHNOLOGY CO., LTD.: BUSINESS OVERVIEW

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX (Page No. – 213)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS


    • 리포트 제목은 자동으로 입력됩니다.
    • *항목은 필수항목입니다.

    의뢰분류*

    성함*

    회사명*

    부서명

    이메일*

    전화번호

    저희 사이트를 알게 된 경로를 가르쳐 주세요.

    문의 내용*

     

    ※개인정보보호정책은여기에서 확인 가능합니다。

    Email 문의도 받고 있습니다.
    아래 주소이며 죄송하지만 "(at)"을 "@"로 바꾸어 보내주시길 부탁드립니다.
    mooneui(at)chosareport-korea.com